<div id="readability-page-1"><p>enGene <span>NASDAQ: ENGN<span></span></span> Chief Executive Officer Ron Cooper used a presentation at the Citizens Life Sciences Conference to outline the company’s approach to non-muscle invasive bladder cancer (NMIBC), emphasizing both the unmet need in the disease and the company’s view that its investigational therapy, detalimogene, could be designed to fit more easily into community urology practices.</p><h2>NMIBC treatment backdrop and the push to delay cystectomy</h2> <p>Cooper characterized the historical options for patients with NMIBC—often older men with comorbidities—as limited, pointing to BCG therapy followed by guideline-recommended radical cystectomy (bladder removal) after BCG failure. He described cystectomy as a major surgery with significant risks, citing a mortality rate of “5%–15%,” high morbidity, and quality-of-life impacts including ostomy use and loss of sexual function. </p><p>He argued that removing the bladder can be an extreme step for a disease he described as slow progressing, noting that NMIBC progresses at “20% over a 10-year timeframe.” Cooper said he is encouraged by the number of new agents entering the market, describing the situation as positive for patients and contributing to a “race” in development driven in part by FDA guidance that can support approvals from relatively small open-label studies in this setting.  </p><h2>Market split: academic centers vs. community practices</h2> <p>Cooper repeatedly highlighted the difference between academic and community settings, estimating that about 17% of patients are treated in academic centers while roughly 83% are treated in the community. He said that many newer products have had limited uptake in community urology because they are “clunky,” require special handling, lengthy thaw times, and can involve insurance complications. </p><p>As Cooper described it, community urologists today generally diagnose and treat patients with BCG and may use intravesical gemcitabine, but often refer patients to academic centers for additional options. In academic settings, he said patients may receive therapies such as Adstiladrin and Keytruda, followed by cystectomy. In the community, he cited ongoing constraints such as long-running BCG supply shortages and limited ability to integrate operationally complex therapies.  </p><h2>Detalimogene’s clinical update and what enGene is watching next</h2> <p>Discussing data from the company’s LEGEND study (cohort 1, which he described as the pivotal cohort), Cooper said enGene reported a six-month complete response (CR) rate of 62% in a data update last fall, calling it comparable to other agents in the category. </p><p>He placed particular emphasis on tolerability and treatment continuity. Cooper said most adverse events observed with detalimogene were grade 1 or 2 and associated with catheterization. He also pointed to low single-digit rates of discontinuations and treatment interruptions, contrasting that with other therapies that he said have higher rates, including figures “in the 40s or higher or in double digits.” To Cooper, those differences suggest patients are more likely to remain on schedule with therapy. </p><p>Looking ahead, Cooper said enGene expects to provide another data update at a spring conference in the second quarter, including final “anytime CR” rates, which he described as the primary endpoint. He said most of the 125 patients in the study will have passed the six-month time point by then. He also previewed an additional update in the second half of the year, when enGene expects to provide 12-month data, describing it as important for assessing longer-term durability. </p><p>Cooper said a filing would follow, with a potential approval in 2027. He also described how durability is assessed in the regulatory context, referencing duration of response (DOR) as a secondary endpoint and discussing 12-month “landmark” comparisons used in the space. While he said he expects immunotherapies to be durable and referenced a small nine-month snapshot from the prior update (five of five eligible patients reaching that mark), he cautioned the study is ongoing.  </p><h2>Operational focus: fitting into community urology workflows</h2> <p>Cooper framed detalimogene’s differentiation as being as much about logistics as clinical performance, arguing that community practices—often under staffing pressure and increasingly influenced by private equity ownership—need therapies that do not disrupt practice flow. He outlined several features he believes would reduce friction in community adoption: </p><ul>   <li>No special handling requirements, in contrast to certain virus-based products that can require decontamination procedures and additional precautions.</li>   <li>Expected storage stability in a regular refrigerator for “many months” and in a freezer for “many years,” which he contrasted with “ultra cold chain” requirements for some therapies.</li>   <li>No need for multiple pre-washes that can consume nursing time and resources.</li>   <li>No need for a procedure room; he described administration as feasible in a standard exam room using typical catheter supplies.</li> </ul> <p>Cooper also discussed time burdens for patients and clinics, suggesting that outside of clinical-trial urine collection requirements, the patient time in-office could be limited to “five or 10 minutes” for administration. He said the company may conduct pharmacoeconomic work over time to quantify potential benefits.  </p><h2>Competitive landscape comments and other LEGEND cohorts</h2> <p>Asked about competitor data (including Protara), Cooper said he viewed certain chemotherapy-oriented approaches as complementary rather than direct competitors, and suggested timelines and evolving FDA guidance could make it harder for late entrants to enroll the relevant third-line populations. He also mentioned Johnson &amp; Johnson’s TAR-200 as part of the evolving community toolkit, while noting operational challenges such as time to place and remove devices and the need for repeat visits. </p><p>Finally, Cooper addressed other LEGEND cohorts—2A (BCG naïve), 2B (BCG exposed), and a papillary-only cohort without CIS—saying enGene had deprioritized those efforts while focusing on cohort 1 recruitment. He said cohort 1 ultimately over-enrolled by 25%, and noted that data from the additional cohorts could later help inform prescribing decisions, with papillary disease potentially relevant for NCCN guideline inclusion.</p><h2>About enGene <span>NASDAQ: ENGN<span></span></span></h2><p>enGene, Inc is a clinical‐stage biopharmaceutical company focused on the development of gene‐based therapeutics for oncology. The company’s core technology is the EnGene Delivery Vehicle (EDV) platform, which employs nonliving, bacterially derived minicells to transport therapeutic payloads directly to tumor cells. By combining targeted delivery with potent payloads, enGene aims to improve the precision and efficacy of cancer treatments while reducing off‐target toxicity. </p><p>Through its EDV platform, enGene has advanced multiple therapeutic candidates into preclinical and clinical stages.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than enGene</li><li>The gold chart Wall Street is terrified of…</li><li>Elon Musk already made me a “wealthy man”</li><li>Silver paying 20% dividend. Plus 68% share gains</li><li>Unlocked: Elon Musk’s Next Big IPO</li><li>1,500 Banks Just Handed the Fed Your Bank Account</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in enGene Right Now?</h2><p>Before you consider enGene, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and enGene wasn't on the list.</p><p>While enGene currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

LABU

IBBQ

<p>enGene CEO Ron Cooper presented at the Citizens Life Sciences Conference, discussing the company's investigational therapy, detalimogene, for non-muscle invasive bladder cancer (NMIBC). He highlighted the limitations of current treatments and the need for community-friendly options. Cooper emphasized the importance of tolerability and treatment continuity, noting a 62% six-month complete response rate in the LEGEND study. He anticipates further data updates in Q2 and a potential filing for approval in 2027, aiming to integrate seamlessly into community urology practices.</p>

Market Beat

Direxion S&P Biotech Bull 3X

VanEck Biotech ETF

Invesco Nasdaq Biotechnology ETF

SPDR S&P Biotech

Proshares Ultra Nasdaq Biotech

Health Care Select Sector SPDR

Invesco Biotechnology & Genome ETF

First Trust NYSE Arca Biotech Index Fd

enGene Therapeutics

iShares Biotechnology ETF

Ark Genomic Revolution ETF

VG Health

ALPS Medical Breakthrough

iShares Global Healthcare

iShares US Pharma

enGene CEO Pitches Detalimogene as Community-Friendly NMIBC Option, Teases Q2 LEGEND Data Update